Free ABPN MCQ Questions and Answers 1

Question 1

Which medication prevents dopamine from being taken up from the synaptic cleft by blocking dopamine transporters?

Accepted Answer

Methlyphenidate

Answer

Methylphenidate primarily acts as a dopamine and norepinephrine reuptake inhibitor. It blocks the dopamine transporter (DAT), preventing dopamine from being reabsorbed into the presynaptic neuron. This action increases dopamine levels in the synaptic cleft, making it the correct answer among the choices.

Question 2

Which medication raises dopamine levels in the synaptic cleft?

Accepted Answer

All of the above

Answer

Both methylphenidate and amphetamine effectively increase dopamine levels in the synaptic cleft. Methylphenidate primarily achieves this by blocking dopamine reuptake, while amphetamine not only blocks reuptake but also promotes the release of dopamine from presynaptic terminals. Thus, both medications contribute to higher synaptic dopamine.

Question 3

What effects on the neuroanatomy of norepinephrine neurons do amphetamine and methlyphenidate have in addition to changing dopamine levels?

Accepted Answer

Suppress locus coeruleus NE neurons

Answer

Stimulants like amphetamine and methylphenidate increase norepinephrine levels in the prefrontal cortex, which is beneficial for ADHD symptoms. However, they also lead to a suppression of the firing rate of norepinephrine neurons in the locus coeruleus (LC), a major source of NE in the brain. This suppression is likely due to increased alpha-2 adrenergic receptor activation and feedback inhibition.

Question 4

Which of the following qualities of bupropion (Wellbutrin) is NOT TRUE?

Accepted Answer

Selective Norepinephrine reuptake inhibitor

Answer

Bupropion (Wellbutrin) is primarily classified as a norepinephrine-dopamine reuptake inhibitor (NDRI). While it does inhibit norepinephrine reuptake, its significant action on dopamine reuptake distinguishes it from a selective norepinephrine reuptake inhibitor (SNRI). Therefore, describing it solely as a selective norepinephrine reuptake inhibitor is not entirely accurate.

Question 5

What Methylphenidate mediation has an osmotic release and lasts for 12 hours?

Accepted Answer

Concerta

Answer

Concerta is an extended-release formulation of methylphenidate that utilizes an osmotic controlled-release oral delivery system (OROS). This technology allows for a gradual and sustained release of the medication over approximately 12 hours, providing effective symptom control with once-daily dosing. This matches the description of osmotic release and 12-hour duration.

American Board of Psychiatry and Neurology Practice Test

American Board of Psychiatry and Neurology Practice Test

Free ABPN MCQ Questions and Answers 1